Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy

PURPOSE: This phase II trial evaluated the efficacy and safety of cixutumumab, a human anti–insulin-like growth factor receptor 1 (IGF-1R) monoclonal IgG1 antibody, and explored potential biomarkers in postmenopausal women with hormone receptor–positive breast cancer. EXPERIMENTAL DESIGN: Patients w...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Cancer Res
Asıl Yazarlar: Gradishar, William J., Yardley, Denise A., Layman, Rachel, Sparano, Joseph A., Chuang, Ellen, Northfelt, Donald W., Schwartz, Gary N., Youssoufian, Hagop, Tang, Shande, Novosiadly, Ruslan, Forest, Amelie, Nguyen, Tuan S., Cosaert, Jan, Grebennik, Dmitri, Haluska, Paul
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2015
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5548297/
https://ncbi.nlm.nih.gov/pubmed/26324738
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-0588
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller